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Abstract. Multiple myeloma (MM)-induced bone disease is mortal for most MM patients. Bisphosphonates are first-line 
treatment for MM-induced bone disease, since it can inhibit osteoclast activity and the resultant bone resorption by suppress-
ing the differentiation of osteoclast precursors into mature osteoclasts, promoting osteoclast apoptosis and disrupting osteo-
clast function. However, it is still unclear whether bisphosphonates have an anti-tumour effect. In our previous work, a com-
putational model was built to simulate the pathology of MM-induced bone disease. This paper extends this proposed compu-
tational model to investigate the efficacy of bisphosphonates treatment and then clear the controversy of this therapy. The 
extended model is validated through the good agreement between simulation results and experimental data. The simulation 
results suggest that bisphosphonates indeed have an anti-tumour effect. 
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1. Introduction 
Multiple myeloma (MM), a haematological malignancy developed in the bone marrow, is the most 
frequent cancer involving bone and the second most common cancer involving blood cells [1]. Bone 
disease, as a major complication of MM, is a fatal danger for MM patients. Up to 60% of MM patients 
suffer a fracture during the disease, and MM induced bone destruction rarely heals [2–5]. Bisphospho-
nates are first-line treatment for MM-induced bone disease [6]. Bisphosphonates are able to target high 
turnover skeletal sites and then bind to the mineralized bone matrix within these sites. After they are 
internalized by osteoclasts, bisphosphonates can inhibit osteoclast activity and the resultant bone re-
sorption by suppressing the differentiation of osteoclast precursors into mature osteoclasts, promoting 
osteoclast apoptosis and disrupting osteoclast function. However, the further investigation is required 
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to investigate the anti-tumour effects of bisphosphonates. Several preclinical and clinical data suggest 
that bisphosphonates may also have a direct anti-tumour effect or an indirect anti-tumour effect [7,8]. 
However, several studies provide contradictory results [9]. 
Computational modelling has demonstrated great potential in biological study [10–15]. In this paper, 
a previously developed computational model of MM-induced bone disease by Ji et al. [14] is extended 
to simulate bisphosphonates treatment against MM-induced bone disease. The simulation results can 
be used to investigate the efficacy of bisphosphonates and clear the controversy of the treatment. 
2. Model development 
The computational model proposed by Ji et al. [14] contains five variables (osteoblast precursors 
(), active osteoblasts (), active osteoclasts (), active MM cells () concentrations and 
bone volume ()) and is made up of following equations: 
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which describe the temporal variations in ,  ,  ,  concentrations and  respectively. 
The model uses ‘Hill functions’ to describe the cellular interaction via the single ligand to receptor 
binding through π functions [16]. The definitions of model parameters including   , 
, "#, ,  !", , , 1, 6 and  are included in [14]. 
As shown in Eqs. (6) and (7), ‘Hill functions’ can both describe the stimulating and inhibiting func-
tions of the ligand-receptor binding in the forms of 
,$%&%'()$
*+,-
 and 
,$%&%'()$
*+,-
, respectively. 
 !"#$% in π functions represents the concentration of ligand in the ligand-receptor binding. &, ', '. 
and ( are parameters related with π functions, and their definitions can be found in [14].  
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In the simulation, the possible direct anti-tumour effects of bisphosphonates are not included in the 
model, since the further investigation is required to confirm this point. The model only considers the 
role of bisphosphonates inhibiting bone resorption by suppressing the differentiation of mature osteoc 
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 Fig. 1. The variation of normalized cell concentrations 
with respect to their initial value during different pe-
riods: the normal (healthy) period from day 1 to day 
50, the invasion of MM cells from day 51 to day 300 
and the intervention of the bisphosphonates therapy 
from day 301. 
Fig. 2. The variation of normalized bone volume with 
respect to its initial value during different periods: the 
normal period from day 1 to day 50, the invasion of MM 
cells from day 51 to day 300 and the intervention of the 
bisphosphonates therapy from day 301. 
 
lasts as well as promoting the apoptosis of osteoclasts. Thus a parameter ‘F.Bi’ which represents the 
degree that the bisphosphonates inhibit bone resorption, is introduced in Eq. (3) to represent the under-
lying mechanism of bisphosphonates treatment. The new equation is presented as follows: 
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for example, when ‘F.Bi’ is set as 0.7, it means that the differentiation rate of active osteoclasts de-
creases to 70% (0.7), while the apoptosis of osteoclasts increases by 30% (0.3 = 1 - 0.7). The previous 
computational model is extended to simulate the efficacy of bisphosphonates treatment through updat-
ing Eq. (3) by Eq. (8). 
3. Simulation results 
In this work, a genetic algorithm is implemented to estimate unknown model parameters. The 
Runge-Kutta (4th and 5th order) integration method, whose corresponding Matlab solver is ode45, is 
selected to solve the model equations. The parameters estimation and model equations solution are 
carried out in Matlab software (version: 7.6.0) [14]. The model solutions represent variations of in 
, , ,  concentrations and  with time respectively.  
Figures 1-3 demonstrate how a bisphosphonates therapy would influence cell concentrations and 
bone volume (F.Bi = 0.7). From day 1 to day 50, the bone microenvironment stays in the stable state 
where cell concentrations of ,  and  , and bone volume nearly keep constant. MM cells 
appear from day 51, disturb the stable state of the bone microenvironment and consequently result in 
the variation of cell concentrations and bone volume. Figure 1 indicates that the bisphosphonates ther-
apy reduces MM concentrations by 16% (for the period considered) and helps bone cell concentrations  
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 Fig. 3. The variation of normalized ratio of OBa:OCa 
with respect to its initial value during different periods: 
the normal period from day 1 to day 50, the invasion of 
MM cells from day 51 to day 300 and the intervention 
of the bisphosphonates therapy from day 301. 
Fig. 4. The variation of normalized MM concentration 
with respect to the value at day 300 after use of the bis-
phosphonates therapy with different values of ‘F.Bi’. 
 
return to their normal values (i.e. values before the invasion of tumour cells). It is should be noted that 
the anti-tumour effects of bisphosphonates are not considered. Therefore the decreased tumour burden 
is due to the inhibited osteoclast activity by bisphosphonates, which agrees with the experimental con-
clusion that the decrease in osteoclast activity can inhibit the proliferation of MM cells [16,17]. As 
illustrated in Figure 3, the OBa:OCa ratio increases by 23% after the introduction of the bisphospho-
nates therapy, which thus results in a significant slowdown of the bone destruction (shown in Figure 2). 
Again, this is confirmed by published data that shows bisphosphonates are beneficial to the suppres-
sion of MM-induced bone destruction [18,19]. 
Figures 4-6 show the variations of MM concentration, bone volume and OBa:OCa ratio caused by 
bisphosphonates with different values of ‘F.Bi’ (0.7, 0.5 and 0.3) for the same treatment strategy. MM 
concentration decreases to 86.8%, 85.2% and 84% of its value at day 300 (for the period considered), 
when ‘Factor.Bisphosphonate’ is set as 0.7, 0.5 and 0.3 (shown in Figure 4). As illustrated in Figure 5, 
when ‘F.Bi’ is set as 0.7, the bone destruction continues although its rate is decreased dramatically, 
however when ‘F.Bi’ is set to 0.5 or 0.3, the bone destruction stops and bone volume begins to in-
crease. Thus, the simulation results suggest that a smaller ‘F.Bi’ produces more significant inhibition 
of MM concentration and bone destruction. The decreased or ceased bone destruction shown in Figure 
5 is due to the increasing OBa:OCa ratio caused by the bisphosphonate treatment demonstrated in Fig-
ure 6.  
In Figures 1-6, the bisphosphonates treatment ends on day 450. The reason why day 450 is chosen as 
terminal time is that as demonstrated in Figures 1 and 3, the concentrations of ,  and , and 
OBa:OCa ratio nearly keep stable around day 450, and after day 450 the trends of curves regarding 
cell concentrations, bone volume (as shown in Figure 7) and OBa:OCa ratio keep the same pattern (the 
simulation of OBa:OCa ratio after day 450 is not given, because it can be calculated based on the data 
from the first figure in Figure 7). 
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Fig. 5. The variation of normalized bone volume with respect 
to its initial value after use of the bisphosphonate therapy 
with different values of ‘F.Bi’. 
Fig. 6. The variation of normalized ratio of OBa:OCa with 
respect to the value at day 300 after use of the bisphospho-
nate therapy with different values of ‘F.Bi’. 
 
  
Fig. 7. The variation of normalized cell concentrations and bone volume with respect to their initial value during different 
periods: the normal (healthy) period from day 1 to day 50, the invasion of MM cells from day 51 to day 300 and the interven-
tion of the bisphosphonates therapy from day 301 to day 600 (F.Bi=0.7). 
4. Conclusion 
In this paper, a computational model of MM-induced bone disease developed in our previous work 
[14] is extended to simulate the underlying mechanism of the bisphosphonates treatment. The ex-
tended computational model is able to simulate how the invasion of MM cells disturbs the stable state 
of the bone microenvironment and causes the fluctuation of cell concentrations and bone volume, and 
how the bisphosphonates treatment helps cell concentrations and bone volume return to their normal 
(healthy) values. The model results compare with published experimental data well and also demon-
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strate that the bisphosphonates treatment is effective in the management of MM-induced bone disease, 
since it can not only suppress osteoclast activity and the resultant bone resorption, but also has anti-
tumour effects which then helps to get rid of the controversy whether the bisphosphonates treatment 
has anti-tumour effects.  
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